Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

• Published in: Rheumatology 2015-04, Vol.54 (4), p.672-677
• Main Authors: Fortunet, Clémentine, Pers, Yves-Marie, Lambert, Joseph, Godfrin-Valnet, Marie, Constant, Elodie, Devilliers, Hervé, Gaudin, Philippe, Jorgensen, Christian, Prades, Béatrice Pallot, Wendling, Daniel, Maillefert, Jean Francis
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - therapeutic use; Adult; Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Drug Therapy, Combination; Female; Glucocorticoids - therapeutic use; Human health and pathology; Humans; Life Sciences; Male; Medication; Middle Aged; Pharmaceutical sciences; Prednisone - therapeutic use; Retrospective Studies; Rhumatology and musculoskeletal system; Treatment Outcome
• ISSN: 1462-0324; 1462-0332; 1460-2172
• DOI: 10.1093/rheumatology/keu339

. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the dose of CS. Inclusion of 130 patients [women 80.8%, mean age 56.7 years (s.d. 14.0), RA duration 16.3 years (s.d. 10.4), mean baseline 28-joint DAS (DAS28) 5.1 (s.d. 1.4), mean baseline dose of CS 10.0 mg/day (s.d. 8.2) prednisone equivalent. Decreases in the mean daily dose of CS and in the DAS28 were observed during follow-up [respectively 6.5 mg (s.d. 4.8) at week 24 (P < 0.0001) and 3.0 mg (s.d. 1.4) at week 24 (P < 0.0001)]. The only variable that correlated with the decrease in the dose of CS was the initial dose of the drug (r = 0.82, P < 0.001). The introduction of TCZ led to rapid and long-lasting CS sparing that did not correlate with the reduction in disease activity. It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity.